Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Cohort Long-term Follow-up Study of Participants From Phase III Clinical Trials of Donaperminogene Seltoplasmid Injection for Critical Limb Ischemia

NCT07023965 is registered in ClinicalTrials.gov with Beijing Northland Biotech. Co., Ltd. as lead sponsor.

NCT NCT07023965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07023965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Cohort Long-term Follow-up Study of Participants From Phase III Clinical Trials of Donaperminogene Seltoplasmid Injection for Critical Limb Ischemia
Lead sponsor
Beijing Northland Biotech. Co., Ltd.
Phase
Observational
Overall status
Enrolling by invitation
Start date
June 30, 2025
Completion date
December 31, 2027
Enrollment
542 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

arterial occlusive disease, arteriosclerosis obliterans, critical limb ischemia (cli), diabetic foot ulcer (dfu), diabetic foot ulcer ischemic, peripheral arterial disease(pad), thromboangiitis obliterans